department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Inluriyo · pharmadog

pharmadog
drugs
Inluriyo

drug

patient view →

imlunestrant tosylate

Marketedupdated 2mo ago

by Eli Lilly and Co

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Unknown, with 1 investigational indication.

all catalysts(1)

approval · 1

INLURIYO (IMLUNESTRANT TOSYLATE) — FDA approval

imlunestrant tosylate

News(0)

no news has mentioned this drug yet

brand

Inluriyo

generic

imlunestrant tosylate

MOA

12.1 Mechanism of Action Imlunestrant is an estrogen receptor (ER) antagonist that binds to ERα. In vitro, imlunestrant induced degradation of ERα, leading to inhibition of ER-dependent gene transcription and cellular proliferation in ER+ breast cancer cells. Imlunestrant demonstrated in vitro and in vivo anti-tumor activity in ER+ breast cancer xenograft models, including models with ESR1 mutations.

indication

Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 50m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Sep 25, 2030

~4.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

Jul 11, 2039compositionUS 10654866
Jul 11, 2039compositionUS 11117902

FDA exclusivities (1)

Sep 25, 2030NCENew Chemical Entity (5y)4.2y

$LLY1200.06-1.14%

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 4

drugINLURIYO4 co-mentions · 1 sources
tagApproval4 co-mentions · 1 sources
companyEli Lilly and Co2 co-mentions · 1 sources
tagSmall Molecule2 co-mentions · 1 sources